Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177325 | 0.93 | CCNT1 (0.36) | PKMPTGER3CCNT1CDK9FFAR4 | |
| SCHEMBL366629 | 0.77 | ACHE (0.40) | CCNT1CDK9L3MBTL1MEN1KMT2A | |
| SCHEMBL10177324 | 0.76 | CCNT1 (0.40) | CCNT1CDK9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12212077 | 0.76 | MEN1 (0.40) | L3MBTL1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL366911 | 0.76 | L3MBTL1 (0.36) | L3MBTL1KMT2ASMN1; SMN2TSHRNPSR1 | |
| SCHEMBL28718137 | 0.74 | CYP1A2 (0.41) | CCNT1CDK9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10177331 | 0.73 | L3MBTL1 (0.34) | CCNT1CDK9L3MBTL1KMT2APOLB | |
| SCHEMBL13978736 | 0.71 | ACHE (0.46) | L3MBTL1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL18922475 | 0.69 | ACHE (0.45) | PKMPTGER3FFAR4L3MBTL1MEN1 | |
| SCHEMBL7088668 | 0.69 | CA12 (0.41) | MEN1KMT2APOLBACHETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3461556-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | AbbVie Ireland Unlimited Company (IE) | 2019-04-03 | — | — | EP | disclosed |
| EP-3461556-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | AbbVie Ireland Unlimited Company (IE) | 2019-04-03 | — | — | EP | disclosed |
| EP-2593226-B1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-11-14 | — | — | EP | disclosed |
| US-9669399-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9669399-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160263566-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2016-09-15 | — | — | US | disclosed |
| US-9381508-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9266913-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150360215-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2015-12-17 | — | — | US | disclosed |
| US-9200021-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150152126-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2015-06-04 | — | — | US | disclosed |
| US-8975443-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140371446-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8841487-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2593226-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | Abbvie Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2012009698-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009698-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371446-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PPIP5K2, ITPA | PKM 1069/4885PTGER3 2576/4885CCNT1 1831/4885 |
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | PKM 1102/4885PTGER3 2766/4885CCNT1 1795/4885 |
| US-20160263566-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | PKM 1102/4885PTGER3 2766/4885CCNT1 1795/4885 |
| US-20150152126-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | PKM 1102/4885PTGER3 2766/4885CCNT1 1795/4885 |
| US-20150360215-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | PKM 1102/4885PTGER3 2766/4885CCNT1 1795/4885 |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PPIP5K2, ITPA | PKM 1069/4885PTGER3 2576/4885CCNT1 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.